Abstract:Abstract Background: Pancreatic cancer(PDAC) remains one of the most lethal cancers worldwide, The accumulation of many abnormal epigenetic abnormalities contribute to the fatal prognosis of PDAC,While available studies are still limited. Many studies have confirmed that the Shc SH2-domain binding protein 1(SHCBP1) plays as proto-oncogene in cancers. However, whether SHCBP1 plays a role in pancreatic cancer oncogenesis is still unknown.EGF domain-specific O-linked GlcNActransferase (EOGT) acts as a key participant in the O-GlcNAcylation of NOTCH1. EOGT mutations inhibit the NOTCH1 signalling pathway and cause several congenital developmental disorders, However, the role of EOGT in malignancies has not been reported.Methods:SHCBP1 and EOGT were identified as proto-oncogenes in PDAC by High-throughput sequencing and Cox regression analysis,and validated by Internal and External cohort and public databases. The function of SHCBP1 and EOGT was determined in vitro and in vivo, The underlying mechanism was investigated by Western blot,Immunofluorescence（IF），Co-immunoprecipitation (Co-IP), Chromatin immunoprecipitation (ChIP)，and luciferase analyses.Results: The expression of EOGT and SHCBP1 was significantly elevated and correlated with worse prognosis in PDAC patients. In vitro, SHCBP1 overexpression promoted pancreatic cancer cell proliferation,migration and invasion, while knocking down SHCBP1 and EOGT inhibited these malignant processes. In vivo data showed that SHCBP1 overexpression promoted xenograft growth and lung metastasis and shortened survival in mice,whereas knocking down either EOGT or SHCBP1 expression suppressed xenograft growth and metastasis and prolonged survival. Morever，EOGT and SHCBP1 enhance the O-GlcNAcylation of NOTCH1, subsequently promoting the nuclear localization of the Notch intracellular domain (NICD) and inhibiting the transcription of E-cadherin and P21 in pancreatic cancer cells.Conclusion:All in all，This research revealed that SHCBP1 and EOGT act as proto-oncogenes in PDAC by enhancing the O-GlcNAcylation of NOTCH1，Which provides a new field of vision for new therapeutic targets for pancreatic cancer.

EGF-induced nuclear localization of SHCBP1 activates β-catenin signaling and promotes cancer progression

SHCBP1 Promotes the Progression of Esophageal Squamous Cell Carcinoma Via the TGFβ Pathway

Β-Catenin Overexpression is Associated with Gefitinib Resistance in Non-Small Cell Lung Cancer Cells.

SH2B1 Promotes Epithelial‐mesenchymal Transition Through the IRS1/β‐catenin Signaling Axis in Lung Adenocarcinoma

SHCBP1 Contributes to the Proliferation and Self‑renewal of Cervical Cancer Cells and Activation of the NF‑κB Signaling Pathway Through EIF5A.

SHCBP1 interacting with EOGT enhanced O-GlcNAcylation of NOTCH1 and promoted the development of pancreatic cancer .

SHCBP1 Interacting with EOGT Enhances O-GlcNAcylation of NOTCH1 and Promotes the Development of Pancreatic Cancer.

SH2B1 Promotes NSCLC Cell Proliferation Through PI3K/Akt/mTOR Signaling Cascade

Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers

CBX8 Promotes Epithelial-mesenchymal Transition, Migration, and Invasion of Lung Cancer through Wnt/β-catenin Signaling Pathway

SHC1 Promotes Lung Cancer Metastasis by Interacting with EGFR

SHC4 orchestrates β-catenin pathway-mediated metastasis in triple-negative breast cancer by promoting Src kinase autophosphorylation

Β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells

Clinical significance of SH2B1 adaptor protein expression in non-small cell lung cancer.

EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis

SHCBP1 promotes synovial sarcoma cell metastasis via targeting TGF-β1/Smad signaling pathway and is associated with poor prognosis

Diverse Targets of β-Catenin during the Epithelial-Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse

Overexpression of SHCBP1 Promotes Migration and Invasion in Gliomas by Activating the NF‐κB Signaling Pathway

Characterization of SHCBP1 to Prognosis and Immunological Landscape in Pan-Cancer: Novel Insights to Biomarker and Therapeutic Targets.

CEBPG Promotes Esophageal Squamous Cell Carcinoma Progression by Enhancing PI3K-AKT Signaling.

Data from CBX8 Exhibits Oncogenic Activity Via AKT/β-Catenin Activation in Hepatocellular Carcinoma